Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nautilus Biotechnology (NAUT) Free Cash Flow (2020 - 2026)

Nautilus Biotechnology has reported Free Cash Flow over the past 7 years, most recently at -$13.6 million for Q1 2026.

  • Quarterly results put Free Cash Flow at -$13.6 million for Q1 2026, up 3.86% from a year ago — trailing twelve months through Mar 2026 was -$51.4 million (up 12.11% YoY), and the annual figure for FY2025 was -$52.0 million, up 15.17%.
  • Free Cash Flow reached -$13.6 million in Q1 2026 per NAUT's latest filing, down from -$12.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$10.5 million in Q3 2022 and bottomed at -$16.9 million in Q1 2024.
  • Median Free Cash Flow over the past 5 years was -$13.7 million (2025), compared with a mean of -$13.5 million.
  • Peak annual rise in Free Cash Flow hit 27.13% in 2022, while the deepest fall reached 90.29% in 2022.
  • Over 5 years, Free Cash Flow stood at -$10.6 million in 2022, then plummeted by 34.95% to -$14.3 million in 2023, then fell by 1.75% to -$14.6 million in 2024, then rose by 13.35% to -$12.6 million in 2025, then fell by 7.85% to -$13.6 million in 2026.
  • Business Quant data shows Free Cash Flow for NAUT at -$13.6 million in Q1 2026, -$12.6 million in Q4 2025, and -$11.5 million in Q3 2025.